CannBioRx Life Sciences C... (ATNFW)
0.01
0.00 (2.04%)
At close: Jan 28, 2025, 3:47 PM
0.01
0.00%
After-hours Jan 28, 2025, 03:48 PM EST
Company Description
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University.
The company was founded by Marc Feldmann, Lawrence J.
Steinman, and Jonathan B.
Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
CannBioRx Life Sciences Corp.
| Country | United States |
| IPO Date | n/a |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Sir Marc Feldmann Ph.D. |
Contact Details
Address: Building 4 Palo Alto, Delaware United States | |
| Website | http://www.180lifesciences.com |
Stock Details
| Ticker Symbol | ATNFW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001690080 |
| CUSIP Number | n/a |
| ISIN Number | US68236V1127 |
| Employer ID | 81-3832378 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder & Director |
| Jason Assad | Director of IR |
| Prof. Jagdeep Nanchahal M.D., Ph.D. | Co-Founder & Chairman of Clinical Advisory Board |
| Sir Marc Feldmann Ph.D. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 27, 2025 | S-1/A | [Amend] Filing |
| Jan 10, 2025 | SCHEDULE 13D | Filing |
| Jan 10, 2025 | D | Filing |
| Jan 03, 2025 | SCHEDULE 13G | Filing |
| Jan 02, 2025 | 8-K/A | [Amend] Current Report |
| Dec 31, 2024 | 8-K | Current Report |
| Dec 31, 2024 | 3 | Filing |
| Dec 30, 2024 | 8-K | Current Report |
| Dec 30, 2024 | 424B5 | Filing |
| Dec 23, 2024 | S-1/A | [Amend] Filing |